Hologic to Purchase Biotheranostics for $230 Million

Hologic has announced that it will acquire Biotheranostics, a developer of tests for breast and metastatic cancers, for approximately $230 million.

San Diego, Calif.-based Biotheranostics offers two polymerase chain reaction (PCR)-based gene expression tests, the Breast Cancer Index diagnostic and the Cancer Type ID metastatic cancer test.

Hologic noted that Biotheranostics’ breast cancer test is widely used in the U.S.  and is included in several clinical practice guidelines. The acquisition is expected to be finalized in February.